Cyclic citrullinated peptide (CCP) antibody has been shown recently to be a promising marker for early detection and diagnosis of rheumatoid arthritis (RA). In order to exploit newly developed therapies for RA, early intervention is crucial in preventing irreversible joint damage. Here, we describe use of a plant expression system to produce a CCP antibody that could be used in the early diagnosis of RA. Heavy and light chain gene sequences of a CCP monoclonal antibody (CCP mAb) were cloned from the hybridoma cell (12G1) and introduced into two separate plant expression vectors under the control of the rice α-amylase 3D (RAmy3D) promoter system. The vectors were introduced into rice calli (Oryza sativa L. cv. Dongjin) using Agrobacterium tumefaciens mediated transformation. Integration of the CCP mAb genes into rice chromosomes was confirmed by a genomic DNA polymerase chain reaction and expression was verified by northern blot analysis of mRNA. The in vivo assembly and secretion of CCP mAb occurred in transgenic rice cell suspension culture under the RAmy3D expression system; accumulated CCP mAbs in the medium were purified by protein G affinity chromatography. Immunoblot assays and ELISA showed these plant-produced CCP mAbs successfully bound to a synthetic CCP antigen. Taken together, our results suggest that CCP mAb produced in a transgenic rice suspension culture were easily purified and biologically active against their antigen in the RA, and thus may be used a specific serological marker, which is present very early in the RA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11248-019-00113-w | DOI Listing |
Diseases
February 2024
College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.
Patients receiving B-cell-depleting therapies (BCDT) are at an increased risk for severe COVID-19. Passive antibody therapy (PAT), including COVID-19 convalescent plasma (CCP) and monoclonal antibodies (mAb), may be an effective treatment in this population. Real-world data on PAT effectiveness are limited.
View Article and Find Full Text PDFAnal Chem
December 2023
Department of Chemistry, Biosystems Research Complex, Clemson University, Clemson, South Carolina 29634-0973, United States.
Cultured cell lines are very commonly used for the mass production of therapeutic proteins, such as monoclonal antibodies (mAbs). In particular, Chinese hamster ovary (CHO) cell lines are widely employed due to their high tolerance to variations in experimental conditions and their ability to grow in suspension or serum free media. CHO cell lines are known for their ability to produce high titers of biotherapeutic products such as immunoglobulin G (IgG).
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
November 2023
Department of Chemistry, Biosystems Research Complex, Clemson University, Clemson, SC 29634-0973, USA. Electronic address:
Protein A (ProA) chromatography is a mainstay in the analytical and preparative scale isolation/purification of monoclonal antibodies (mAbs). One area of interest is continuous processing or continuous chromatography, where ProA chromatography is used in the large-scale purification of mAbs. However, filtration is required prior to all ProA isolations to remove large particulates in cell culture supernatant, consisting of a mixture of cell debris, host cell contaminants, media components, etc.
View Article and Find Full Text PDFNeurol Educ
September 2023
From the Department of Neurology (R.A.-D., C.L.), University of Chicago Medical Center, University of Chicago, IL; Department of Neurology (F.G.S.V.), The University of Oklahoma Health Sciences Center, Oklahoma City; Department of Neurology (H.A.K.), Massachusetts General Hospital and Brigham and Women Hospital, Harvard Medical School, Boston; Department of Medicine (Neurology; Critical Care) (N.N.), The Ottawa Hospital, Ontario, Canada; Department of Neurology (E.C.), Columbia University Medical Center; Department of Neurology (E.C.), Cornell University School of Medicine, New York, NY; Department of Neurology (C.C.-P.), Seattle Children's Hospital, University of Washington, Seattle; Department of Neurology (M.P.), Yale School of Medicine, New Haven, CT; Department of Intensive Care Medicine (D.K.), St. James's Hospital, Dublin, and Global Brain Health Institute, Trinity College Dublin, Ireland; Department of Neurology (S.G.), University of Florida, Gainesville; Department of Neurology (M.S.E.), University of Pennsylvania, Philadelphia, PA; Department of Neurology (N.S.D.), Icahn School of Medicine at Mount Sinai, New York, NY; Department of Neurology and Neurosurgery (M.-A.B.), Neurological Institute, Cleveland Clinic Foundation (Florida), Port St. Lucie; Department of Neurology (A.R.R.), Henry Ford Health, Detroit, MI; Department of Neurology and Neurosurgery (C.A.), Emory University School of Medicine, Atlanta, GA; and Department of Neurology (N.A.M.), Program in Trauma, University of Maryland School of Medicine, Baltimore.
Introduction And Problem Statement: The Neurocritical Care (NCC) Society Resident and Fellow Task Force's NEURON study concluded that learners had significant concerns regarding the need for educational improvement in NCC. To address these shortcomings, we identified the lack of an educational curriculum for trainees in NCC and developed a Twitter-based educational curriculum for trainees to improve knowledge in NCC.
Objectives: The objectives of this study were to describe the pathophysiology, delineate a systematic diagnostic approach, and apply evidence-based strategies in the management of diseases in NCC.
Heliyon
March 2023
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of Monoclonal Antibody Products, National Institutes for Food and Drug Control, Beijing, China.
Anti-drug antibody (ADA) positivity is correlated with disease relapse risk when treated with monoclonal antibody (mAb) therapeutics. ADA evaluation can assist with interpreting pharmacokinetic, pharmacological, and toxicology results. Here, we established an ADA assay based on two steps of acid dissociation combined with a bridging immunoassay to provide a comprehensive validation strategy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!